Veterinary Pharmacy Giant Wedgewood Recalls Wide Range of Pet Medications Over Potency Concerns

Wedgewood Pharmacy, a major compounding pharmacy that supplies customized medications to veterinarians and pet owners across the United States, announced a voluntary nationwide recall on Wednesday of a broad swath of its compounded animal drugs, saying it cannot be confident the products contain the correct dose of active ingredient.

The recall notice, posted on the Food and Drug Administration's website, says the New Jersey-based company identified "inconsistencies in the reliability of certain analytical testing data generated by their laboratory," meaning some in-date products already in circulation could be either subpotent or superpotent. Low potency can leave a sick animal's condition inadequately treated; excess potency raises the risk of toxicity or overdose, the notice says.

What is being pulled from shelves

The recall covers an unusually wide range of dosage forms rather than a single product: powders, pastes, oral suspensions, injectables, ophthalmic ointments and solutions, ear preparations, topical sprays and gels. The affected medications were shipped nationwide to veterinary practices, pharmacies and other customers between February 18 and October 6 of this year, according to the FDA posting. They were compounded for companion animals, horses, exotic and zoo animals, wildlife and aquatic species; the company says none were intended for food-producing animals.

Because compounded drugs are formulated one batch at a time for specific patients rather than mass-manufactured, Wedgewood is not naming the individual products in its public notice. Instead, the company has directed veterinarians and pet owners to a lot-lookup tool on its website where customers can search by product and lot number to determine whether medication already in their possession is affected.

The numbers

Wedgewood's FDA filing states that the company "has received 98 complaints, of which 7 are serious" connected to the affected lots. The notice does not specify how many individual units or prescriptions are covered, a detail that is often omitted from compounding-pharmacy recalls because, unlike recalls of mass-produced drugs, each lot can correspond to a comparatively small number of dispensed doses. In a separate recall information page on its own site, Wedgewood adds a somewhat softer note, saying it has "not identified an increase in reported complaints or adverse events" since the recall was initiated, and that the action is a precautionary one taken because the company lacks confidence in its own testing data rather than because of a confirmed spike in harm.

The company says the recall is being carried out with the FDA's knowledge. It was first discovered, Wedgewood says, through its own internal quality-control review rather than through a regulator's inspection or an outside complaint.

Who is affected, and what they are being told to do

The practical burden of the recall falls first on veterinary clinics and pharmacies that stock Wedgewood's compounded drugs, and then on the pet, horse and exotic-animal owners who were dispensed them. The company's instructions, repeated on both the FDA notice and its own site, are straightforward: businesses should immediately check their inventory against the lookup tool, quarantine any affected stock, and notify their own customers if they already dispensed it; animal owners who have affected product should stop using it, keep the container, and call their veterinarian with any medical concerns rather than simply discontinuing a chronic medication on their own.

Wedgewood has retained the claims-management firm Sedgwick to coordinate the recall response, including direct outreach to affected customers by email and mail. Both the company and Sedgwick can be reached at the same recall hotline, 866-562-5931, on weekdays from 8 a.m. to 9 p.m. Eastern and Saturdays from 9 a.m. to 5 p.m.

The health risks involved with low potency can include ineffective treatment, and the health risks involved with high potency can include toxicity or overdose.

Owners and veterinarians who believe an animal had an adverse reaction, or who have a quality complaint about a Wedgewood product, are directed to report it to the FDA's Center for Veterinary Medicine at 1-888-FDA-VETS or through the agency's online adverse-event reporting system, separate from Wedgewood's own recall line.

A recurring issue in a loosely regulated corner of medicine

Compounded drugs occupy a different regulatory lane than conventional, mass-manufactured medications. Veterinarians turn to compounding pharmacies when a commercially approved drug does not exist in a needed strength, flavor or form for a particular species — a flavored liquid for a cat that will not take a pill, for instance, or a reduced-strength dose for a small exotic animal. But because each preparation is custom-made rather than produced and tested under the FDA's standard drug-approval process, compounded veterinary medications are not independently verified for potency or sterility before they reach an animal.

That gap has produced a recurring pattern of enforcement activity. The FDA maintains a running public list of inspections, recalls and other actions taken against firms that compound animal drugs, spanning dozens of companies and more than a decade of citations for problems including insufficient sterility assurance, potency deviations, insanitary manufacturing conditions and mislabeling. The agency's history with this particular company includes a prior Class II recall of a compounded suspension and a separate recall of hand-filled transdermal gels, both tied to manufacturing or labeling problems rather than the laboratory-testing concern cited this week.

What happens next

Wedgewood says it is working with prescribing veterinarians to identify clinically appropriate alternative medications where the recall disrupts an animal's ongoing treatment, stressing that any change in a chronic prescription should be made in consultation with the treating veterinarian rather than by an owner acting alone. The company has not said how long its review of the underlying testing-data problem will take, when it expects to resume normal distribution of the affected product categories, or whether the lab issue originated with its own staff or an outside testing contractor.

The FDA listing for the recall remains open, with no termination date yet posted, meaning the agency has not yet signed off on Wedgewood's corrective actions. Given the volume and variety of products involved — and a company customer base that includes a large share of the country's general veterinary practices — the practical effect is likely to unfold over the coming days and weeks as individual clinics work through the lot-lookup tool and contact affected clients one prescription at a time.